Assembly Biosciences Inc
$ 29.81
1.26%
15 Apr - close price
- Market Cap 472,867,000 USD
- Current Price $ 29.81
- High / Low $ 30.05 / 29.28
- Stock P/E N/A
- Book Value 13.04
- EPS -0.55
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.05 %
- 52 Week High 39.71
- 52 Week Low 9.82
About
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$48.75
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-12-31 | 2025-11-10 | 2025-08-06 | 2025-05-06 | 2025-03-26 | 2024-11-06 | 2024-08-08 | 2024-05-08 | 2024-01-31 | 2023-11-08 | 2023-08-09 | 2023-05-04 |
| Reported EPS | 2.48 | -0.72 | -1.33 | -1.17 | -1.57 | -1.51 | -2.05 | -1.66 | -2.15 | -0.27 | -0.32 | -0.37 |
| Estimated EPS | -0.8467 | -1.57 | -1.61 | -1.6 | -1.75 | -2.02 | -2.23 | -3.23 | -2.88 | -0.23 | -0.29 | -0.35 |
| Surprise | 3.3267 | 0.85 | 0.28 | 0.43 | 0.18 | 0.51 | 0.18 | 1.57 | 0.73 | -0.04 | -0.03 | -0.02 |
| Surprise Percentage | 392.9019% | 54.1401% | 17.3913% | 26.875% | 10.2857% | 25.2475% | 8.0717% | 48.6068% | 25.3472% | -17.3913% | -10.3448% | -5.7143% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.73 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ASMB
2026-04-14 08:46:00
This article analyzes Assembly Biosciences Inc. (NASDAQ: ASMB), highlighting a near-term neutral sentiment but mid- and long-term strength. It details an exceptional 75.2:1 risk-reward setup targeting a 21.2% gain, and provides three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
2026-04-11 00:40:02
This article from TradingView provides an overview of options volatility for Assembly Biosciences, Inc. (NASDAQ:ASMB). It presents implied volatility curves and ATM IV term structure for various expiration dates, helping users assess market expectations and craft options strategies. The content is primarily a data display page rather than a traditional article.
2026-04-10 23:40:02
This page displays the options chain for Assembly Biosciences, Inc. (ASMB) on the Nasdaq Stock Market. It provides data for call and put options, including pricing, Greeks, and implied volatility, allowing users to track market movements and evaluate risks.
2026-04-10 02:10:23
This page provides a comprehensive resource for Assembly Biosciences (ASMB) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, and 8-K material events, with AI-powered summaries. Recent filings detail financing activities, clinical trial results for HSV-2 and HBV programs, and insider ownership changes. The documents offer insights into the company's financial status, operational progress, and strategic collaborations, particularly with Gilead Sciences.
2026-04-09 12:09:08
Assembly Biosciences announced that positive Phase 1b data for its investigational HSV helicase-primase inhibitors, ABI-5366 and ABI-1179, will be presented at ESCMID Global 2026. ABI-5366 has been selected for an oral presentation and two posters, while ABI-1179 will be featured as a late-breaker poster. These candidates are exclusively licensed to Gilead, which holds sole responsibility for their further clinical development and commercialization.
2026-04-09 12:09:08
Assembly Biosciences announced that positive Phase 1b clinical data for its herpes simplex virus (HSV) helicase-primase inhibitor candidates, ABI-5366 and ABI-1179, will be presented at the ESCMID Global 2026 conference. ABI-5366 data, including results from a monthly dosing cohort, has been selected for an oral presentation, while ABI-1179 data will be featured in a late-breaker poster presentation, highlighting their potential as long-acting therapeutic options for recurrent genital herpes. These investigational candidates are exclusively licensed to Gilead Sciences for further development and commercialization.
